Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD

27.85  -0.37 (-1.31%)

After market: 27.85 0 (0%)

Fundamental Rating

4

Taking everything into account, CGON scores 4 out of 10 in our fundamental rating. CGON was compared to 571 industry peers in the Biotechnology industry. While CGON has a great health rating, there are worries on its profitability. CGON has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CGON has reported negative net income.
In the past year CGON has reported a negative cash flow from operations.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of -14.17%, CGON belongs to the best of the industry, outperforming 84.55% of the companies in the same industry.
CGON's Return On Equity of -14.59% is amongst the best of the industry. CGON outperforms 89.70% of its industry peers.
Industry RankSector Rank
ROA -14.17%
ROE -14.59%
ROIC N/A
ROA(3y)-31.66%
ROA(5y)N/A
ROE(3y)-39.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -10K -20K -30K

More info and screens

9

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGON has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for CGON has been reduced compared to a year ago.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

CGON has an Altman-Z score of 79.77. This indicates that CGON is financially healthy and has little risk of bankruptcy at the moment.
CGON's Altman-Z score of 79.77 is amongst the best of the industry. CGON outperforms 98.93% of its industry peers.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 79.77
ROIC/WACCN/A
WACC9.5%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 35.32 indicates that CGON has no problem at all paying its short term obligations.
CGON has a better Current ratio (35.32) than 98.22% of its industry peers.
CGON has a Quick Ratio of 35.32. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
CGON's Quick ratio of 35.32 is amongst the best of the industry. CGON outperforms 98.22% of its industry peers.
Industry RankSector Rank
Current Ratio 35.32
Quick Ratio 35.32
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

CGON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.78%.
Looking at the last year, CGON shows a small growth in Revenue. The Revenue has grown by 6.81% in the last year.
EPS 1Y (TTM)-54.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
Revenue 1Y (TTM)6.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.82%

3.2 Future

The Earnings Per Share is expected to decrease by -7.38% on average over the next years.
The Revenue is expected to grow by 423.44% on average over the next years. This is a very strong growth
EPS Next Y1.8%
EPS Next 2Y-16.87%
EPS Next 3Y-7.38%
EPS Next 5YN/A
Revenue Next Year412.82%
Revenue Next 2Y102.14%
Revenue Next 3Y867.35%
Revenue Next 5Y423.45%

3.3 Evolution

CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A cheap valuation may be justified as CGON's earnings are expected to decrease with -7.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.87%
EPS Next 3Y-7.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (2/21/2025, 8:08:12 PM)

After market: 27.85 0 (0%)

27.85

-0.37 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners95.99%
Inst Owner Change-98.51%
Ins Owners1.54%
Ins Owner Change0%
Market Cap2.08B
Analysts82.86
Price Target69.8 (150.63%)
Short Float %10.09%
Short Ratio9.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.05%
Min EPS beat(2)19.89%
Max EPS beat(2)26.21%
EPS beat(4)2
Avg EPS beat(4)-127.58%
Min EPS beat(4)-534.71%
Max EPS beat(4)26.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-48.91%
Min Revenue beat(2)-59.54%
Max Revenue beat(2)-38.28%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.62%
PT rev (3m)1.05%
EPS NQ rev (1m)3.95%
EPS NQ rev (3m)17.05%
EPS NY rev (1m)0.41%
EPS NY rev (3m)5.94%
Revenue NQ rev (1m)495.35%
Revenue NQ rev (3m)-63.7%
Revenue NY rev (1m)-16.67%
Revenue NY rev (3m)-49.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3047.21
P/FCF N/A
P/OCF N/A
P/B 3.88
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-5.31
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0.01
BVpS7.17
TBVpS7.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.17%
ROE -14.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.66%
ROA(5y)N/A
ROE(3y)-39.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 35.32
Quick Ratio 35.32
Altman-Z 79.77
F-Score6
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
EPS Next Y1.8%
EPS Next 2Y-16.87%
EPS Next 3Y-7.38%
EPS Next 5YN/A
Revenue 1Y (TTM)6.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.82%
Revenue Next Year412.82%
Revenue Next 2Y102.14%
Revenue Next 3Y867.35%
Revenue Next 5Y423.45%
EBIT growth 1Y-57.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-89.21%
EBIT Next 3Y-30.29%
EBIT Next 5YN/A
FCF growth 1Y-53.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.26%
OCF growth 3YN/A
OCF growth 5YN/A